Ziritaxestat Failure Could Spell End For Gilead/Galapagos Pact
IPF And Systemic Sclerosis Trials Abandoned
Executive Summary
The Galapagos and Gilead partnership has had a tough few months and the failure of ziritaxestat, plus the decision not to develop filgotinib Stateside for rheumatoid arthritis, is calling into question the merits of the whole collaboration for the US biotech.
You may also be interested in...
Harbingers For IPF Drug Development
Roche’s decision to discontinue a Phase III program in idiopathic pulmonary fibrosis was the latest of several recent late-stage clinical failures, emblematic of the difficulty in finding new approaches to treat the disease.
Galapagos Keeps Analysts Guessing About Future Plans
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.
Boehringer Bids To Go Beyond Slowing IPF
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.